Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shaji Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljević, Rachid Baz, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Christopher R. D’Angelo, Benjamin A. Derman, Srinivas Devarakonda, Noura Elsedawy, Alfred L. Garfall, Kelly Godby, Jens Hillengaß, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Hans C. Lee, Michaela Liedtke, Thomas G. Martin, James Omel, Timothy Robinson, Aaron S. Rosenberg, Douglas W. Sborov, Mark A. Schroeder, Daniel W. Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Varshavsky‐Yanovsky, Jenna Snedeker, Rashmi Kumar
Abstract
The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.